How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

E.g. frequency of Bortezomib, dosing of Bortezomib, length of cycles.

Answer from: Medical Oncologist at Academic Institution

My modifications based off the GRIFFIN trial (Voorhees et al., PMID 32325490) are as follows: If patients have high burden disease and no underlying neuropathy, I will start with twice-weekly bortezomib (days 1, 4, 8, 11) but will change the dexamethasone to 20 mg days 1, 4, 8, 11, and 15 using...

Comments

Medical Oncologist at Wellspan Health
Thanks Dr. @Holstein, what is your practice regard...

Medical Oncologist at University of Nebraska Medical Center
I never use them. With the use of subcutaneous Dar...

Medical Oncologist at Wellspan Health
Makes sense. Thanks a lot!

Please select the option that best describes you:

How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

Related Questions